1
|
Maganin AG, Souza GR, Fonseca MD, Lopes AH, Mano Guimarães RM, Dagostin A, Cecilio NT, Mendes AS, Gonçalves WA, Silva CE, Fernandes Gomes FI, Mauriz Marques LM, Silva RL, Arruda LM, Santana DA, Lemos H, Huang L, Davoli-Ferreira M, Santana-Coelho DS, Sant'Anna MB, Kusuda R, Talbot J, Pacholczyk G, Buqui GA, Lopes N, Alves-Filho JC, Leão RM, O'Connor JC, Cunha FQ, Mellor A, Cunha T. Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice. J Clin Invest 2022; 132:153805. [PMID: 36227694 DOI: 10.1172/jci153805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Accepted: 10/11/2022] [Indexed: 11/17/2022] Open
Abstract
Neuropathic pain is one of the most important clinical consequences of injury to the somatosensory system. Nevertheless, the critical pathophysiological mechanisms involved in neuropathic pain development are poorly understood. In this study, we found that neuropathic pain is abrogated when the kynurenine metabolic pathway initiated by the enzyme indoleamine 2,3-dioxygenase (IDO1) is ablated pharmacologically or genetically. Mechanistically, it was found that IDO1-expressing dendritic cells (DCs) accumulated in the dorsal root leptomeninges and led to an increase in kynurenine levels in the spinal cord. In the spinal cord, kynurenine was metabolized by kynurenine-3-monooxygenase-expressing astrocytes into a pro-nociceptive metabolite 3-hydroxykynurenine. Ultimately, 3-hydroxyanthranilate 3,4-dioxygenase-derived quinolinic acid formed in the final step of the canonical KYNPATH was also involved in neuropathic pain development through the activation of the glutamatergic N-methyl-D-aspartate (NMDA) receptor. In conclusion, these data revealed a novel role for DCs driving neuropathic pain development through elevation of the kynurenine metabolic pathway. This novel paradigm offers potential new targets for drug development against this type of chronic pain.
Collapse
Affiliation(s)
- Alexandre Gm Maganin
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Guilherme R Souza
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Miriam D Fonseca
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Alexandre H Lopes
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Rafaela M Mano Guimarães
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - André Dagostin
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Nerry T Cecilio
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Atlante S Mendes
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - William A Gonçalves
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Conceição Ea Silva
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | | | - Lucas M Mauriz Marques
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Rangel L Silva
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Letícia M Arruda
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Denis A Santana
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Henrique Lemos
- Cancer Immunology, Inflammation and Tolerance Program, Cancer Center, Georgia Regents University, Augusta, United States of America
| | - Lei Huang
- Cancer Immunology, Inflammation and Tolerance Program, Cancer Center, Georgia Regents University, Augusta, United States of America
| | - Marcela Davoli-Ferreira
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Danielle S Santana-Coelho
- Department of Pharmacology, University of Texas Health Science Center at San Antonio and Audie L. Murphy VA Hospital, San Antonio, United States of America
| | - Morena B Sant'Anna
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Ricardo Kusuda
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Jhimmy Talbot
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Gabriela Pacholczyk
- Cancer Immunology, Inflammation and Tolerance Program, Cancer Center, Georgia Regents University, Augusta, United States of America
| | - Gabriela A Buqui
- NPPNS, Department of Physic and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Norberto Lopes
- NPPNS, Department of Physic and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Jose C Alves-Filho
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Ricardo M Leão
- Graduate Program in Basic and Applied Immunology Ribeirao Preto Medical Sch, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Jason C O'Connor
- Department of Pharmacolog, University of Texas Health Science Center at San Antonio and Audie L. Murphy VA Hospital, San Antonio, United States of America
| | - Fernando Q Cunha
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| | - Andrew Mellor
- Cancer Immunology, Inflammation and Tolerance Program, Cancer Center, Georgia Regents University, Augusta, United States of America
| | - Thiago Cunha
- Department of Pharmacology, University of São Paulo at Ribeirão Preto Medical School, Ribeirao Preto, Brazil
| |
Collapse
|
3
|
Dagostin A, Ferrari M. In vivo bonding mechanism of an experimental dual-cure enamel-dentin bonding system. Am J Dent 2001; 14:105-8. [PMID: 11507796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE To evaluate, in vivo, the formation of hybrid layer, resin tags and adhesive lateral branches, by an experimental dual-curing "one-bottle" enamel-dentin bonding system. MATERIALS AND METHODS The new dentin adhesive (Excite DSC) was tested in five Class V restorations placed in vital, periodontally compromised teeth. The experimental bonding system was used in combination with a flowable composite. After 1 wk the teeth were extracted and processed for SEM evaluation. All the samples were split-fractured along their long axis. Half of the samples were used to evaluate hybrid layer formation and the other half to examine the morphology of resin tags. RESULTS The experimental adhesive system showed a micromechanical bonding mechanism to conditioned dentin with formation of a hybrid layer, resin tags and adhesive lateral branches. SEM photomicrographs of the decalcified samples showed a high density of resin tags and uniform distribution along the cavity walls.
Collapse
Affiliation(s)
- A Dagostin
- Department of Dental Materials, University of Siena, Italy
| | | |
Collapse
|